Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Biotech
Intellia opts out of hemophilia gene editing work with Regeneron
Intellia is opting out of a hemophilia program, leaving the CRISPR/Cas9 gene editing work on factor IX treatments in the hands of partner Regeneron.
Annalee Armstrong
Mar 22, 2024 11:21am
Metagenomi, Telomir offer double test case for preclinical IPOs
Feb 9, 2024 7:00am
Gene editing biotech Metagenomi plans modest $87M IPO
Feb 5, 2024 9:14am
Genevant secures $114M deal with Tome to develop liver therapy
Jan 16, 2024 10:11am
JPM24, Day 3: Gene editors talk BD; Roivant has cash to spend
Jan 10, 2024 4:38pm
CRISPR Tx director: It’s ‘still early days’ on sealing new deals
Jan 10, 2024 10:57am